Updated recommendations for the treatment of rheumatoid arthritis: Another step on a long road

Arthritis Care and Research

Volumn 64, Issue 5, 2012, Pages 648-651

  Daikh, David I ^a   William St Clair, E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; METHOTREXATE; RITUXIMAB;

CANCER RISK; CHRONIC DISEASE; HUMAN; LYMPHOMA; MELANOMA; MONOTHERAPY; NONHODGKIN LYMPHOMA; PATIENT CARE; REVIEW; RHEUMATOID ARTHRITIS; SKIN CANCER; T CELL LYMPHOMA;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RHEUMATOLOGY;

EID: 84859862757     PISSN: 00043591     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21659     Document Type: Review

References (12)

1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
2. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84. (Pubitemid 351847559)
3. Shekelle P. The appropriateness method. Med Decis Making 2004;24:228-31. (Pubitemid 38391941)
4. Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/ CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. Executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Vasc Med 2011;16:35-77.
5. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6. (Pubitemid 351632017)
6. Grade Working Group. Introduction. Grading the quality of evidence and the strength of recommendations. URL: www. gradeworkinggroup.org.
7. Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 2012;64: 640-7.
8. Food and Drug Administration. Follow-up to the June 4, 2008 early communication about the ongoing safety review of tumor necrosis factor (TNF) blockers. URL: www.fda.gov/Drugs/ DrugSafety/ PostmarketDrugSafetyInformationforPatientsand Providers/ DrugSafetyInformationforHeathcareProfessionals/ ucm174449.htm.
9. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7. (Pubitemid 46175082)
10. Parakkal D, Sifuentes H, Semer R, Ehrenpreis ED. Hepatosplenic T-cell lymphoma in patients receiving TNF-inhibitor therapy: expanding the groups at risk. Eur J Gastroenterol Hepatol 2011;23:1150-6.
11. Raaschou P, Simard JF, Neovius M, Askling J. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum 2011;63:1812-22.
12. Solomon DH, Mercer E, Kavanaugh A. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results [review]. Arthritis Rheum 2012;64:21-32.